Reubi, Jean Claude; Waser, Beatrice (2015). Triple-peptide receptor targeting in vitro allows detection of all tested gut and bronchial NETs. Journal of nuclear medicine, 56(4), pp. 613-615. Society of Nuclear Medicine 10.2967/jnumed.114.153189
Text
J Nucl Med-2015-Reubi-613-5.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (720kB) |
UNLABELLED
A high proportion of gut and bronchial neuroendocrine tumors (NETs) overexpresses somatostatin receptors, especially the sst2 subtype. It has also recently been observed that incretin receptors, namely glucagonlike peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptors, can be overexpressed in gut and bronchial NETs. However, because not all tumors can express these receptors in sufficient amounts, in vivo imaging with a single radioligand may not always be successful. We therefore evaluated with in vitro methods whether a cocktail of radioligands targeting these 3 receptors would improve tumor labeling.
METHODS
In vitro receptor autoradiography was performed on 55 NETs, comparing in each successive section of tumor the binding with a single radioligand, either (125)I-Tyr(3)-octreotide, (125)I-GLP-1(7-36)amide, or (125)I-GIP(1-30), with the binding using a cocktail of all 3 radioligands, given concomitantly under identical experimental conditions.
RESULTS
Using the cocktail of radioligands, all tumors without exception showed moderate to very high binding, with a receptor density corresponding to 1,000-10,000 dpm/mg of tissue; conversely, single-ligand binding, although identifying most tumors as receptor-positive, failed to detect receptors or measured only a low density of receptors below 1,000 dpm/mg in a significant number of tumors. In addition, the cocktail of radioligands always provided a homogeneous labeling of the whole tumor, whereas single radioligands occasionally showed heterogeneous labeling.
CONCLUSION
The study suggests that the use of a cocktail of 3 radioligands binding to somatostatin receptors, GLP-1 receptors, and GIP receptors would allow detecting virtually all NETs and labeling them homogeneously in vivo, representing a significant improvement for imaging and therapy in NETs.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Service Sector > Institute of Pathology |
UniBE Contributor: |
Reubi-Kattenbusch, Jean-Claude, Waser, Beatrice |
Subjects: |
500 Science > 570 Life sciences; biology 600 Technology > 610 Medicine & health |
ISSN: |
0161-5505 |
Publisher: |
Society of Nuclear Medicine |
Language: |
English |
Submitter: |
Doris Haefelin |
Date Deposited: |
13 Jul 2015 13:58 |
Last Modified: |
05 Dec 2022 14:48 |
Publisher DOI: |
10.2967/jnumed.114.153189 |
PubMed ID: |
25698785 |
Uncontrolled Keywords: |
GLP-1 receptors; incretin receptors; multireceptor imaging; neuroendocrine tumors; somatostatin receptors |
BORIS DOI: |
10.7892/boris.70212 |
URI: |
https://boris.unibe.ch/id/eprint/70212 |